LitCovid-sample-Enju  

PMC:7228307 / 59629-62087 JSONTXT 18 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T356 0-6 NNP denotes Future
T357 7-18 NNP denotes Engineering
T358 19-29 NNPS denotes Strategies
T359 30-40 JJ denotes Monoclonal
T360 41-51 NNS denotes antibodies
T361 52-55 VBP denotes are
T362 56-62 JJ denotes potent
T363 63-75 NNS denotes therapeutics
T364 76-78 IN denotes in
T365 79-80 DT denotes a
T366 81-87 NN denotes number
T367 88-90 IN denotes of
T368 91-98 JJ denotes chronic
T369 99-101 CC denotes or
T370 102-106 RB denotes once
T371 107-116 JJ denotes incurable
T372 117-125 NNS denotes diseases
T373 127-134 RB denotes However
T374 134-135 -COMMA- denotes ,
T375 136-141 EX denotes there
T376 142-144 VBZ denotes is
T377 145-150 RB denotes still
T378 151-160 JJ denotes extensive
T379 161-166 JJ denotes unmet
T380 167-175 JJ denotes clinical
T381 176-180 NN denotes need
T382 181-183 RB denotes as
T383 184-188 RB denotes well
T384 189-191 IN denotes as
T385 192-204 JJ denotes considerable
T386 205-209 NN denotes room
T387 210-213 IN denotes for
T388 214-225 NN denotes improvement
T389 226-228 IN denotes in
T390 229-233 JJ denotes many
T391 234-242 VBG denotes existing
T392 243-255 NNS denotes therapeutics
T393 257-264 JJ denotes Further
T394 265-278 NN denotes understanding
T395 279-281 IN denotes of
T396 282-285 WRB denotes how
T397 286-294 NN denotes antibody
T398 295-304 NN denotes structure
T399 305-312 VBZ denotes affects
T400 313-317 NN denotes FcγR
T401 318-326 NN denotes function
T402 327-329 VBZ denotes is
T403 330-339 JJ denotes essential
T404 340-343 IN denotes for
T405 344-350 JJ denotes future
T406 351-362 NN denotes development
T407 363-365 IN denotes of
T408 366-370 RBR denotes more
T409 371-377 JJ denotes potent
T410 378-381 CC denotes and
T411 382-391 JJ denotes effective
T412 392-396 NNS denotes mAbs
T413 398-405 RB denotes Already
T414 405-406 -COMMA- denotes ,
T415 407-418 NN denotes engineering
T416 419-421 IN denotes of
T417 422-425 DT denotes the
T418 426-429 NN denotes IgG
T419 430-432 NN denotes Fc
T420 433-436 CC denotes and
T421 437-440 PRP-DOLLAR- denotes its
T422 441-447 NN denotes glycan
T423 448-451 VBZ denotes has
T424 452-458 VBN denotes proved
T425 459-460 DT denotes a
T426 461-467 JJ denotes potent
T427 468-471 CC denotes and
T428 472-481 JJ denotes effective
T429 482-490 NN denotes approach
T430 491-494 IN denotes for
T431 495-505 VBG denotes increasing
T432 506-509 DT denotes the
T433 510-518 JJ denotes clinical
T434 519-532 NN denotes effectiveness
T435 532-533 -COMMA- denotes ,
T436 534-544 JJ denotes functional
T437 545-556 NN denotes specificity
T438 557-560 CC denotes and
T439 561-567 NN denotes safety
T440 568-570 IN denotes of
T441 571-582 JJ denotes therapeutic
T442 583-587 NNS denotes mAbs
T443 588-591 CC denotes and
T444 592-594 VBZ denotes is
T445 595-597 DT denotes an
T446 598-606 VBG denotes emerging
T447 607-614 NN denotes pathway
T448 615-617 TO denotes to
T449 618-621 DT denotes the
T450 622-633 NN denotes development
T451 634-636 IN denotes of
T452 637-640 DT denotes the
T453 641-651 NN denotes “next‐gen”
T454 652-664 NNS denotes therapeutics
T455 666-672 JJ denotes Future
T456 673-683 NNS denotes directions
T457 684-686 IN denotes in
T458 687-690 DT denotes the
T459 691-702 NN denotes development
T460 703-706 CC denotes and
T461 707-710 NN denotes use
T462 711-713 IN denotes of
T463 714-725 JJ denotes therapeutic
T464 726-736 NNS denotes antibodies
T465 737-743 MD denotes should
T466 744-756 RB denotes increasingly
T467 757-762 VB denotes mimic
T468 763-769 JJ denotes normal
T469 770-780 JJ denotes protective
T470 781-789 NN denotes antibody
T471 790-799 NNS denotes responses
T472 799-800 -COMMA- denotes ,
T473 801-806 WDT denotes which
T474 807-810 VBP denotes are
T475 811-821 JJ denotes polyclonal
T476 822-825 CC denotes and
T477 826-834 VBN denotes elicited
T478 835-837 IN denotes in
T479 838-841 DT denotes the
T480 842-849 NN denotes context
T481 850-852 IN denotes of
T482 853-859 JJ denotes innate
T483 860-868 NN denotes receptor
T484 869-879 NN denotes engagement
T485 880-885 WDT denotes which
T486 886-894 VBZ denotes includes
T487 895-898 DT denotes the
T488 899-902 NNS denotes FcR
T489 903-905 RB denotes as
T490 906-910 RB denotes well
T491 911-913 IN denotes as
T492 914-919 JJ denotes other
T493 920-930 RB denotes powerfully
T494 931-941 JJ denotes responsive
T495 942-949 NNS denotes systems
T496 950-959 VBG denotes including
T497 960-963 DT denotes the
T498 964-973 JJ denotes Toll‐like
T499 974-983 NNS denotes receptors
T500 984-987 CC denotes and
T501 988-998 NN denotes complement
T502 999-1008 NNS denotes receptors
T503 1010-1021 RB denotes Furthermore
T504 1021-1022 -COMMA- denotes ,
T505 1023-1026 DT denotes the
T506 1027-1032 JJ denotes mixed
T507 1033-1041 NN denotes subclass
T508 1042-1048 NN denotes nature
T509 1049-1051 IN denotes of
T510 1052-1057 DT denotes these
T511 1058-1064 JJ denotes normal
T512 1065-1073 NN denotes antibody
T513 1074-1083 NNS denotes responses
T514 1084-1092 VBZ denotes suggests
T515 1093-1097 IN denotes that
T516 1098-1111 NNS denotes circumstances
T517 1112-1115 MD denotes may
T518 1116-1121 VB denotes arise
T519 1122-1124 IN denotes in
T520 1125-1136 JJ denotes therapeutic
T521 1137-1147 NNS denotes strategies
T522 1148-1153 WRB denotes where
T523 1154-1159 EX denotes there
T524 1160-1162 VBZ denotes is
T525 1163-1168 NN denotes value
T526 1169-1171 IN denotes in
T527 1172-1178 VBG denotes having
T528 1179-1189 RB denotes distinctly
T529 1190-1198 VBN denotes modified
T530 1199-1202 NNS denotes Fcs
T531 1203-1206 IN denotes for
T532 1207-1210 DT denotes the
T533 1211-1218 JJ denotes nuanced
T534 1219-1229 NN denotes engagement
T535 1230-1232 IN denotes of
T536 1233-1242 JJ denotes different
T537 1243-1247 NN denotes FcγR
T538 1248-1254 NN denotes family
T539 1255-1262 NNS denotes members
T540 1264-1274 NNS denotes Treatments
T541 1275-1285 VBG denotes comprising
T542 1286-1294 JJ denotes multiple
T543 1295-1299 NNS denotes mAbs
T544 1300-1303 CC denotes and
T545 1304-1310 JJ denotes immune
T546 1311-1321 NNS denotes stimulants
T547 1322-1325 VBP denotes are
T548 1326-1331 IN denotes under
T549 1332-1345 NN denotes investigation
T550 1346-1348 IN denotes in
T551 1349-1359 JJ denotes infectious
T552 1360-1367 NN denotes disease
T553 1368-1371 IN denotes for
T554 1372-1386 NN denotes neutralization
T555 1387-1395 NN denotes coverage
T556 1396-1398 IN denotes of
T557 1399-1406 JJ denotes variant
T558 1407-1414 NNS denotes strains
T559 1416-1422 RB denotes Indeed
T560 1422-1423 -COMMA- denotes ,
T561 1424-1428 PDT denotes such
T562 1429-1431 DT denotes an
T563 1432-1440 NN denotes approach
T564 1441-1444 MD denotes may
T565 1445-1447 VB denotes be
T566 1448-1452 RBS denotes most
T567 1453-1462 JJ denotes effective
T568 1463-1465 IN denotes in
T569 1466-1474 VBG denotes emerging
T570 1475-1485 JJ denotes infectious
T571 1486-1493 NN denotes disease
T572 1494-1498 JJ denotes such
T573 1499-1501 IN denotes as
T574 1502-1508 JJ denotes severe
T575 1509-1514 JJ denotes acute
T576 1515-1526 JJ denotes respiratory
T577 1527-1535 NN denotes syndrome
T578 1536-1547 NN denotes coronavirus
T579 1548-1549 CD denotes 2
T580 1550-1551 -LRB- denotes (
T581 1551-1561 NN denotes SARS‐CoV‐2
T582 1561-1562 -RRB- denotes )
T583 1563-1572 NN denotes infection
T584 1574-1577 DT denotes The
T585 1578-1581 NN denotes use
T586 1582-1584 IN denotes of
T587 1585-1593 JJ denotes multiple
T588 1594-1598 NNS denotes mAbs
T589 1599-1607 VBN denotes tailored
T590 1608-1611 IN denotes for
T591 1612-1620 JJ denotes distinct
T592 1621-1629 NN denotes effector
T593 1630-1639 NNS denotes functions
T594 1640-1643 CC denotes and
T595 1644-1653 VBG denotes targeting
T596 1654-1663 JJ denotes different
T597 1664-1672 NNS denotes epitopes
T598 1673-1677 MD denotes will
T599 1678-1686 VB denotes maximize
T600 1687-1690 DT denotes the
T601 1691-1702 NN denotes opportunity
T602 1703-1706 IN denotes for
T603 1707-1718 NN denotes cocktailing
T604 1719-1721 IN denotes of
T605 1722-1730 NN denotes effector
T606 1731-1740 NNS denotes functions
T607 1741-1743 IN denotes in
T608 1744-1753 JJ denotes different
T609 1754-1759 NNS denotes types
T610 1760-1762 IN denotes of
T611 1763-1771 NNS denotes diseases
T612 1773-1779 RB denotes Indeed
T613 1779-1780 -COMMA- denotes ,
T614 1781-1783 IN denotes in
T615 1784-1785 DT denotes a
T616 1786-1791 JJ denotes small
T617 1792-1795 CC denotes but
T618 1796-1808 JJ denotes contemporary
T619 1809-1816 NN denotes example
T620 1817-1824 IN denotes outside
T621 1825-1827 IN denotes of
T622 1828-1838 JJ denotes infectious
T623 1839-1846 NN denotes disease
T624 1846-1847 -COMMA- denotes ,
T625 1848-1851 DT denotes the
T626 1852-1864 NNP denotes FDA‐approved
T627 1865-1876 NN denotes combination
T628 1877-1879 IN denotes in
T629 1880-1894 NN denotes adenocarcinoma
T630 1895-1902 NN denotes therapy
T631 1903-1907 VBZ denotes uses
T632 1908-1909 DT denotes a
T633 1910-1918 NN denotes cocktail
T634 1919-1921 IN denotes of
T635 1922-1925 CD denotes two
T636 1926-1930 NNS denotes mAbs
T637 1930-1931 -COMMA- denotes ,
T638 1932-1942 NN denotes pertuzumab
T639 1943-1946 CC denotes and
T640 1947-1958 NN denotes trastuzumab
T641 1958-1959 -COMMA- denotes ,
T642 1960-1967 IN denotes against
T643 1968-1976 NN denotes Her2.123
T644 1977-1983 RB denotes Rather
T645 1984-1988 IN denotes than
T646 1989-1992 CD denotes one
T647 1993-1997 NN denotes type
T648 1998-2000 IN denotes of
T649 2001-2003 NN denotes Fc
T650 2004-2006 TO denotes to
T651 2007-2014 VB denotes conquer
T652 2015-2018 DT denotes all
T653 2018-2019 -COMMA- denotes ,
T654 2020-2023 DT denotes the
T655 2024-2032 JJ denotes combined
T656 2033-2036 NN denotes use
T657 2037-2039 IN denotes of
T658 2040-2053 RB denotes appropriately
T659 2054-2062 VBN denotes selected
T660 2063-2067 NNS denotes mAbs
T661 2068-2073 WP-DOLLAR- denotes whose
T662 2074-2084 JJ denotes individual
T663 2085-2095 NNS denotes components
T664 2096-2099 VBP denotes are
T665 2100-2108 VBN denotes enhanced
T666 2109-2112 IN denotes for
T667 2113-2116 DT denotes the
T668 2117-2127 NN denotes engagement
T669 2128-2130 IN denotes of
T670 2131-2140 JJ denotes different
T671 2141-2145 NN denotes FcγR
T672 2146-2153 NNS denotes members
T673 2154-2157 MD denotes may
T674 2158-2165 VB denotes utilize
T675 2166-2174 JJ denotes multiple
T676 2175-2185 NNS denotes components
T677 2186-2188 IN denotes of
T678 2189-2192 DT denotes the
T679 2193-2201 NN denotes spectrum
T680 2202-2204 IN denotes of
T681 2205-2213 NN denotes effector
T682 2214-2223 NNS denotes responses
T683 2224-2226 IN denotes on
T684 2227-2232 NN denotes offer
T685 2233-2235 IN denotes by
T686 2236-2239 DT denotes the
T687 2240-2246 JJ denotes immune
T688 2247-2253 NN denotes system
T689 2255-2259 JJ denotes Such
T690 2260-2270 NN denotes “next‐gen”
T691 2271-2280 NNS denotes biologics
T692 2281-2285 MD denotes will
T693 2286-2291 VB denotes begin
T694 2292-2294 TO denotes to
T695 2295-2302 VB denotes realize
T696 2303-2306 DT denotes the
T697 2307-2311 JJ denotes full
T698 2312-2321 NN denotes potential
T699 2322-2324 IN denotes of
T700 2325-2338 JJ denotes FcγR‐mediated
T701 2339-2347 NN denotes antibody
T702 2348-2354 JJ denotes immune
T703 2355-2367 NNS denotes therapeutics
T704 2368-2371 CC denotes and
T705 2372-2377 VB denotes offer
T706 2378-2394 JJ denotes transformational
T707 2395-2401 NN denotes change
T708 2402-2405 IN denotes for
T709 2406-2409 DT denotes the
T710 2410-2419 NN denotes treatment
T711 2420-2422 IN denotes of
T712 2423-2434 JJ denotes intractable
T713 2435-2438 CC denotes and
T714 2439-2448 JJ denotes incurable
T715 2449-2457 NNS denotes diseases
R367 T358 T356 arg1Of Strategies,Future
R368 T358 T357 arg1Of Strategies,Engineering
R369 T360 T359 arg1Of antibodies,Monoclonal
R370 T360 T361 arg1Of antibodies,are
R371 T363 T361 arg2Of therapeutics,are
R372 T363 T362 arg1Of therapeutics,potent
R373 T361 T364 arg1Of are,in
R374 T366 T364 arg2Of number,in
R375 T366 T365 arg1Of number,a
R376 T366 T367 arg1Of number,of
R377 T372 T367 arg2Of diseases,of
R378 T372 T368 arg1Of diseases,chronic
R379 T368 T369 arg1Of chronic,or
R380 T371 T369 arg2Of incurable,or
R381 T371 T370 arg1Of incurable,once
R382 T372 T371 arg1Of diseases,incurable
R383 T376 T373 arg1Of is,However
R384 T376 T374 arg1Of is,","
R385 T375 T376 arg1Of there,is
R386 T384 T376 arg2Of as,is
R387 T376 T377 arg1Of is,still
R388 T380 T378 arg1Of clinical,extensive
R389 T380 T379 arg1Of clinical,unmet
R390 T381 T380 arg1Of need,clinical
R391 T384 T382 arg1Of as,as
R392 T384 T383 arg1Of as,well
R393 T381 T384 arg1Of need,as
R394 T386 T384 arg2Of room,as
R395 T386 T385 arg1Of room,considerable
R396 T386 T387 arg1Of room,for
R397 T388 T387 arg2Of improvement,for
R398 T388 T389 arg1Of improvement,in
R399 T392 T389 arg2Of therapeutics,in
R400 T392 T390 arg1Of therapeutics,many
R401 T392 T391 arg1Of therapeutics,existing
R402 T394 T393 arg1Of understanding,Further
R403 T394 T395 arg1Of understanding,of
R404 T396 T395 arg2Of how,of
R405 T399 T396 arg1Of affects,how
R406 T398 T397 arg1Of structure,antibody
R407 T398 T399 arg1Of structure,affects
R408 T401 T399 arg2Of function,affects
R409 T401 T400 arg1Of function,FcγR
R410 T394 T402 arg1Of understanding,is
R411 T403 T402 arg2Of essential,is
R412 T394 T403 arg1Of understanding,essential
R413 T403 T404 arg1Of essential,for
R414 T406 T404 arg2Of development,for
R415 T406 T405 arg1Of development,future
R416 T406 T407 arg1Of development,of
R417 T412 T407 arg2Of mAbs,of
R418 T412 T408 arg1Of mAbs,more
R419 T412 T409 arg1Of mAbs,potent
R420 T409 T410 arg1Of potent,and
R421 T411 T410 arg2Of effective,and
R422 T412 T411 arg1Of mAbs,effective
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement
R517 T514 T503 arg1Of suggests,Furthermore
R518 T514 T504 arg1Of suggests,","
R519 T508 T505 arg1Of nature,the
R520 T508 T506 arg1Of nature,mixed
R521 T508 T507 arg1Of nature,subclass
R522 T508 T509 arg1Of nature,of
R523 T513 T509 arg2Of responses,of
R524 T513 T510 arg1Of responses,these
R525 T513 T511 arg1Of responses,normal
R526 T513 T512 arg1Of responses,antibody
R527 T508 T514 arg1Of nature,suggests
R528 T518 T514 arg2Of arise,suggests
R529 T518 T515 arg1Of arise,that
R530 T516 T517 arg1Of circumstances,may
R531 T518 T517 arg2Of arise,may
R532 T516 T518 arg1Of circumstances,arise
R533 T518 T519 arg1Of arise,in
R534 T521 T519 arg2Of strategies,in
R535 T521 T520 arg1Of strategies,therapeutic
R536 T521 T522 arg1Of strategies,where
R537 T524 T522 arg2Of is,where
R538 T523 T524 arg1Of there,is
R539 T525 T524 arg2Of value,is
R540 T525 T526 arg1Of value,in
R541 T527 T526 arg2Of having,in
R542 T530 T527 arg2Of Fcs,having
R543 T530 T528 arg1Of Fcs,distinctly
R544 T530 T529 arg2Of Fcs,modified
R545 T530 T531 arg1Of Fcs,for
R546 T534 T531 arg2Of engagement,for
R547 T534 T532 arg1Of engagement,the
R548 T534 T533 arg1Of engagement,nuanced
R549 T534 T535 arg1Of engagement,of
R550 T539 T535 arg2Of members,of
R551 T539 T536 arg1Of members,different
R552 T539 T537 arg1Of members,FcγR
R553 T539 T538 arg1Of members,family
R554 T540 T541 arg1Of Treatments,comprising
R555 T544 T541 arg2Of and,comprising
R556 T543 T542 arg1Of mAbs,multiple
R557 T543 T544 arg1Of mAbs,and
R558 T546 T544 arg2Of stimulants,and
R559 T546 T545 arg1Of stimulants,immune
R560 T540 T547 arg1Of Treatments,are
R561 T548 T547 arg2Of under,are
R562 T540 T548 arg1Of Treatments,under
R563 T549 T548 arg2Of investigation,under
R564 T547 T550 arg1Of are,in
R565 T552 T550 arg2Of disease,in
R566 T552 T551 arg1Of disease,infectious
R567 T552 T553 arg1Of disease,for
R568 T555 T553 arg2Of coverage,for
R569 T555 T554 arg1Of coverage,neutralization
R570 T555 T556 arg1Of coverage,of
R571 T558 T556 arg2Of strains,of
R572 T558 T557 arg1Of strains,variant
R573 T565 T559 arg1Of be,Indeed
R574 T565 T560 arg1Of be,","
R575 T563 T561 arg1Of approach,such
R576 T563 T562 arg1Of approach,an
R577 T563 T564 arg1Of approach,may
R578 T565 T564 arg2Of be,may
R579 T563 T565 arg1Of approach,be
R580 T567 T565 arg2Of effective,be
R581 T567 T566 arg1Of effective,most
R582 T563 T567 arg1Of approach,effective
R583 T567 T568 arg1Of effective,in
R584 T569 T568 arg2Of emerging,in
R585 T571 T569 arg2Of disease,emerging
R586 T571 T570 arg1Of disease,infectious
R587 T573 T572 arg1Of as,such
R588 T571 T573 arg1Of disease,as
R589 T583 T573 arg2Of infection,as
R590 T576 T574 arg1Of respiratory,severe
R591 T576 T575 arg1Of respiratory,acute
R592 T583 T576 arg1Of infection,respiratory
R593 T583 T577 arg1Of infection,syndrome
R594 T583 T578 arg1Of infection,coronavirus
R595 T583 T579 arg1Of infection,2
R596 T583 T580 arg1Of infection,(
R597 T581 T580 arg2Of SARS‐CoV‐2,(
R598 T582 T580 arg3Of ),(
R599 T585 T584 arg1Of use,The
R600 T585 T586 arg1Of use,of
R601 T588 T586 arg2Of mAbs,of
R602 T588 T587 arg1Of mAbs,multiple
R603 T588 T589 arg2Of mAbs,tailored
R604 T589 T590 arg1Of tailored,for
R605 T593 T590 arg2Of functions,for
R606 T593 T591 arg1Of functions,distinct
R607 T593 T592 arg1Of functions,effector
R608 T589 T594 arg1Of tailored,and
R609 T595 T594 arg2Of targeting,and
R610 T588 T595 arg1Of mAbs,targeting
R611 T597 T595 arg2Of epitopes,targeting
R612 T597 T596 arg1Of epitopes,different
R613 T585 T598 arg1Of use,will
R614 T599 T598 arg2Of maximize,will
R615 T585 T599 arg1Of use,maximize
R616 T601 T599 arg2Of opportunity,maximize
R617 T601 T600 arg1Of opportunity,the
R618 T601 T602 arg1Of opportunity,for
R619 T603 T602 arg2Of cocktailing,for
R620 T603 T604 arg1Of cocktailing,of
R621 T606 T604 arg2Of functions,of
R622 T606 T605 arg1Of functions,effector
R623 T599 T607 arg1Of maximize,in
R624 T609 T607 arg2Of types,in
R625 T609 T608 arg1Of types,different
R626 T609 T610 arg1Of types,of
R627 T611 T610 arg2Of diseases,of
R628 T631 T612 arg1Of uses,Indeed
R629 T631 T613 arg1Of uses,","
R630 T631 T614 arg1Of uses,in
R631 T619 T614 arg2Of example,in
R632 T619 T615 arg1Of example,a
R633 T619 T616 arg1Of example,small
R634 T616 T617 arg1Of small,but
R635 T618 T617 arg2Of contemporary,but
R636 T619 T618 arg1Of example,contemporary
R637 T619 T620 arg1Of example,outside
R638 T620 T621 arg1Of outside,of
R639 T623 T621 arg2Of disease,of
R640 T623 T622 arg1Of disease,infectious
R641 T631 T624 arg1Of uses,","
R642 T627 T625 arg1Of combination,the
R643 T627 T626 arg1Of combination,FDA‐approved
R644 T627 T628 arg1Of combination,in
R645 T630 T628 arg2Of therapy,in
R646 T630 T629 arg1Of therapy,adenocarcinoma
R647 T627 T631 arg1Of combination,uses
R648 T633 T631 arg2Of cocktail,uses
R649 T633 T632 arg1Of cocktail,a
R650 T633 T634 arg1Of cocktail,of
R651 T636 T634 arg2Of mAbs,of
R652 T636 T635 arg1Of mAbs,two
R653 T633 T637 arg1Of cocktail,","
R654 T639 T637 arg2Of and,","
R655 T638 T639 arg1Of pertuzumab,and
R656 T640 T639 arg2Of trastuzumab,and
R657 T631 T641 arg1Of uses,","
R658 T631 T642 arg1Of uses,against
R659 T643 T642 arg2Of Her2.123,against
R660 T674 T644 arg1Of utilize,Rather
R661 T644 T645 arg1Of Rather,than
R662 T647 T645 arg2Of type,than
R663 T647 T646 arg1Of type,one
R664 T647 T648 arg1Of type,of
R665 T649 T648 arg2Of Fc,of
R666 T651 T650 arg1Of conquer,to
R667 T647 T650 modOf type,to
R668 T652 T651 arg2Of all,conquer
R669 T674 T653 arg1Of utilize,","
R670 T656 T654 arg1Of use,the
R671 T656 T655 arg1Of use,combined
R672 T656 T657 arg1Of use,of
R673 T660 T657 arg2Of mAbs,of
R674 T659 T658 arg1Of selected,appropriately
R675 T660 T659 arg1Of mAbs,selected
R676 T663 T661 arg1Of components,whose
R677 T660 T661 arg2Of mAbs,whose
R678 T663 T662 arg1Of components,individual
R679 T663 T664 arg1Of components,are
R680 T665 T664 arg2Of enhanced,are
R681 T663 T665 arg2Of components,enhanced
R682 T665 T666 arg1Of enhanced,for
R683 T668 T666 arg2Of engagement,for
R684 T668 T667 arg1Of engagement,the
R685 T668 T669 arg1Of engagement,of
R686 T672 T669 arg2Of members,of
R687 T672 T670 arg1Of members,different
R688 T672 T671 arg1Of members,FcγR
R689 T656 T673 arg1Of use,may
R690 T674 T673 arg2Of utilize,may
R691 T656 T674 arg1Of use,utilize
R692 T676 T674 arg2Of components,utilize
R693 T676 T675 arg1Of components,multiple
R694 T676 T677 arg1Of components,of
R695 T679 T677 arg2Of spectrum,of
R696 T679 T678 arg1Of spectrum,the
R697 T679 T680 arg1Of spectrum,of
R698 T682 T680 arg2Of responses,of
R699 T682 T681 arg1Of responses,effector
R700 T679 T683 arg1Of spectrum,on
R701 T684 T683 arg2Of offer,on
R702 T674 T685 arg1Of utilize,by
R703 T688 T685 arg2Of system,by
R704 T688 T686 arg1Of system,the
R705 T688 T687 arg1Of system,immune
R706 T691 T689 arg1Of biologics,Such
R707 T691 T690 arg1Of biologics,“next‐gen”
R708 T691 T692 arg1Of biologics,will
R709 T693 T692 arg2Of begin,will
R710 T691 T693 arg1Of biologics,begin
R711 T704 T693 arg2Of and,begin
R712 T704 T694 arg1Of and,to
R713 T691 T695 arg1Of biologics,realize
R714 T698 T695 arg2Of potential,realize
R715 T698 T696 arg1Of potential,the
R716 T698 T697 arg1Of potential,full
R717 T698 T699 arg1Of potential,of
R718 T703 T699 arg2Of therapeutics,of
R719 T703 T700 arg1Of therapeutics,FcγR‐mediated
R720 T703 T701 arg1Of therapeutics,antibody
R721 T703 T702 arg1Of therapeutics,immune
R722 T695 T704 arg1Of realize,and
R723 T705 T704 arg2Of offer,and
R724 T691 T705 arg1Of biologics,offer
R725 T707 T705 arg2Of change,offer
R726 T707 T706 arg1Of change,transformational
R727 T705 T708 arg1Of offer,for
R728 T710 T708 arg2Of treatment,for
R729 T710 T709 arg1Of treatment,the
R730 T710 T711 arg1Of treatment,of
R731 T715 T711 arg2Of diseases,of
R732 T715 T712 arg1Of diseases,intractable
R733 T712 T713 arg1Of intractable,and
R734 T714 T713 arg2Of incurable,and
R735 T715 T714 arg1Of diseases,incurable